JP7701786B2 - Carbonate aerosol skin preparation - Google Patents

Description

The present invention relates to a carbonic acid aerosol skin preparation for topical use.

Heparinoids have many hydrophilic groups in their structure, such as sulfate, carboxyl, and hydroxyl groups, and have pharmacological effects such as moisturizing and anti-inflammatory effects. The efficacy of topical skin preparations containing heparinoids is said to be the treatment and prevention of thrombophlebitis (including hemorrhoids), pain and inflammatory diseases due to circulatory disorders (induration and pain after injection), chilblains, hypertrophic scars and keloids, progressive keratoderma tylodes palmaris, asteatosis, swelling, hematoma, tendonitis, muscle pain, and arthritis after trauma (bruises, sprains, contusions), and muscular torticollis (infancy). Heparinoid-containing topical skin preparations are sold in the form of creams, soft ointments, lotions, and foam sprays.

Of these dosage forms, foam sprays are expected to prevent dripping at the affected area compared to lotions, and are easier to spread on the affected area compared to creams and ointments. For example, Patent Document 1 describes a screen former composition that contains a heparinoid, a nonionic surfactant, and a specific polyol, and that enables foam to be formed by a screen former without using a foaming gas, in consideration of the fact that liquefied natural gas is irritating to the skin. On the other hand, Patent Document 2 describes a foamable composition that contains a heparinoid and a specific nonionic surfactant, and is made up of a concentrate that does not contain lower alcohol, and a propellant.

On the other hand, carbon dioxide gas is known to promote blood circulation and have a warming effect, and aerosol-type cosmetics that use carbon dioxide gas as a propellant are in use (for example, Patent Document 3).

JP 2019-172703 A JP 2016-180012 A JP 2018-43932 A

The screen former composition described in Reference 1 is difficult to create fine foam, and friction is easily felt when applied. In addition, the foaming composition described in Reference 2 uses LPG as a propellant, which causes problems with skin irritation. Furthermore, the pH of both formulations is adjusted to be close to neutral, which tends to be higher than the pH of the skin, which is slightly acidic.

The inventors therefore conducted extensive research to develop a carbon dioxide aerosol skin preparation containing a heparinoid. However, it was discovered that the stable pH range of heparinoids is near neutral, and the mixture of the aerosol concentrate and carbon dioxide gas in the pressure-resistant container becomes acidic, resulting in problems with the storage stability of the heparinoid.

The present invention therefore relates to a carbonate aerosol skin preparation that contains a stable blend of heparinoids and is minimally irritating to the skin.

The inventors have found that the above problem can be solved by using carbon dioxide gas as a propellant, adding a pH adjuster to the original solution together with a heparinoid, and adjusting the pH of the mixture with carbon dioxide gas to 4.5 or more and 7.0 or less.

The present invention provides a carbonated aerosol skin preparation for topical use, which comprises an aerosol concentrate containing the following components (A) to (C) and a propellant containing component (D), and the pH of the mixture of the aerosol concentrate and the propellant is 4.5 or higher and 7.0 or lower.
(A) Heparinoids
(B) pH adjuster
(C) Water
(D) Carbon dioxide

The carbon dioxide aerosol skin preparation of the present invention contains a stable blend of heparinoids and causes minimal irritation to the skin.

Aerosol concentrate The aerosol concentrate in the carbonated aerosol skin preparation for external use of the present invention contains the following components (A) to (C).

[Component (A): Heparinoid]
The heparinoid of component (A) is also known as mucopolysaccharide polysulfate or heparinoid, and is a polysulfated mucopolysaccharide having a repeating unit of a disaccharide consisting of D-glucuronic acid and N-acetyl-D-galactosamine. As the heparinoid, a heparinoid listed in the Japanese Pharmacopoeia Non-Drug Standards 2002 is preferable.

The average molecular weight of the heparinoid is not particularly limited, but from the viewpoint of medicinal effects such as moisturizing action, 1000 to 1,000,000 Mw is preferable, and 5000 to 100,000 Mw is particularly preferable. In addition, the amount (%) of organic sulfate groups in the heparinoid is not particularly limited, but from the viewpoint of medicinal effects such as moisturizing action, 20 to 40% is preferable, and 25 to 38% is more preferable. The amount of organic sulfate groups is measured by the method described in the section on "heparinoids" in the Japanese Pharmacopoeia Non-Drug Standards 2002.

The content of component (A) in the aerosol concentrate is preferably 0.05% by mass or more, more preferably 0.07% by mass or more, and even more preferably 0.1% by mass or more, from the viewpoints of efficacy such as moisturizing effect, usability, etc., and is preferably 0.6% by mass or less, more preferably 0.5% by mass or less, and even more preferably 0.4% by mass or less. The specific range of the content of component (A) in the aerosol concentrate is preferably 0.05 to 0.6% by mass, more preferably 0.07 to 0.5% by mass, and even more preferably 0.1 to 0.4% by mass.

[Component (B): pH adjuster]
The pH adjuster of component (B) is preferably one or more compounds selected from the group consisting of organic acids, organic acid salts, amino acids, amino acid salts, amines, inorganic acids, inorganic acid salts, and inorganic bases. Examples of organic acids include glycolic acid, citric acid, malic acid, succinic acid, tartaric acid, lactic acid, etc., and examples of salts thereof include potassium salts and sodium salts. Examples of amino acids include glutamic acid, aspartic acid, arginine, lysine, etc., and examples of salts thereof include sodium salts, hydrochlorides, and succinates. Examples of amines include aliphatic amines such as monoethanolamine, triethanolamine, methylamine, ethylamine, trimethylamine, triethylamine, ethylenediamine, and tetramethylethylenediamine. Examples of inorganic acids include phosphoric acid, and examples of inorganic acid salts include potassium dihydrogen phosphate and disodium hydrogen phosphate. Examples of inorganic bases include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, and potassium hydroxide. Among these, from the viewpoint of enhancing the stability of the heparinoid, organic acids, organic acid salts, amino acids, amino acid salts, amines, and inorganic bases are preferred.

The content of component (B) in the aerosol concentrate is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.15% by mass or more, and is preferably 1.0% by mass or less, more preferably 0.7% by mass or less, even more preferably 0.5% by mass or less. The specific range of the content of component (B) in the aerosol concentrate is preferably 0.05 to 1.0% by mass, more preferably 0.1 to 0.7% by mass, even more preferably 0.15 to 0.5% by mass.

From the viewpoint of the stability of the heparinoid, the mass ratio (A)/(B) of component (A) to component (B) in the aerosol concentrate is preferably 0.05 or more, more preferably 0.1 or more, even more preferably 0.2 or more, and is preferably 12 or less, more preferably 5 or less, even more preferably 2.5 or less. The specific range of the mass ratio (A)/(B) of component (A) to component (B) in the aerosol concentrate is preferably 0.05 to 12, more preferably 0.1 to 5, even more preferably 0.2 to 2.5.

[Component (C): Water]
The content of water in the aerosol concentrate is preferably 10% by mass or more, more preferably 20% by mass or more, and even more preferably 40% by mass or more, and is preferably 90% by mass or less, more preferably 85% by mass or less, and even more preferably 80% by mass or less, from the viewpoints of the penetration of the ejected agent into the skin and the solubility of the heparinoid and other components. The specific range of the content of component (C) in the aerosol concentrate is preferably 10 to 90% by mass, more preferably 20 to 85% by mass, and even more preferably 40 to 80% by mass.

[Component (E): Water-soluble polymer]
The aerosol concentrate may further contain a water-soluble polymer as component (E). The water-soluble polymer is not limited as long as it is one that is used in ordinary skin topical preparations, and examples thereof include plant-based polymers, microbial polymers, mucopolysaccharides, cellulose-based polymers, starch-based polymers, vinyl-based polymers, acrylic-based polymers, and polyoxyethylene-based polymers. The weight-average molecular weight of the water-soluble polymer of component (E) is preferably 10,000 or more. The weight-average molecular weight is measured using a gel permeation chromatography (GPC)-multi-angle laser light scattering detector (MALLS) system using polyethylene oxide as the standard substance.

Examples of plant-based polymers include gum arabic, locust bean gum, guar gum, karaya gum, carrageenan, pectin, agar, and starch (rice, corn, potato, and wheat), and examples of microbial-based polymers include xanthan gum and gellan gum. Examples of mucopolysaccharides include hyaluronic acid, tuberose polysaccharide, and tremella fuciformis polysaccharide. Examples of cellulose-based polymers include methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose stearoxy ether, nitrocellulose, sodium cellulose sulfate, sodium carboxymethylcellulose, crystalline cellulose, cellulose powder, hydroxyethylcellulose hydroxypropylstearylether hydroxypropylsulfonate, and the like. Examples of starch-based polymers include carboxymethylstarch and methylhydroxypropylstarch. Examples of vinyl-based polymers include polyvinyl methyl ether, polyvinylpyrrolidone, and carboxyvinyl polymer. Examples of acrylic polymers include sodium polyacrylate, polyethyl acrylate, polyacrylic acid amide, acrylic acid/alkyl (meth)acrylate copolymer, (sodium acrylate/sodium acryloyldimethyl taurate) copolymer, polyacrylate crosspolymer-6, 2-methacryloyloxyethyl phosphorylcholine/butyl methacrylate copolymer, etc. Examples of polyoxyethylene polymers include polyethylene oxide, etc.

Among these, from the viewpoint of maintaining the agent in a weakly acidic state after ejection and from the viewpoint of reducing friction during application, water-soluble polymers having a sugar skeleton, such as plant-based polymers, microbial polymers, mucopolysaccharides, cellulose-based polymers, and starch-based polymers, are preferred, cellulose-based polymers are more preferred, and hydroxypropyl methylcellulose, hydroxypropyl methylcellulose stearoxy ether, and hydroxyethyl cellulose are even more preferred.

The content of component (E) in the aerosol concentrate is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, even more preferably 0.10% by mass or more, even more preferably 0.20% by mass or more, and is preferably 5.0% by mass or less, more preferably 2.0% by mass or less, even more preferably 1.0% by mass or less, even more preferably 0.80% by mass or less, from the viewpoint of maintaining the agent weakly acidic after ejection and from the viewpoint of reducing friction during application. The specific range of the content of component (E) in the aerosol concentrate is preferably 0.01 to 5.0% by mass, more preferably 0.05 to 2.0% by mass, even more preferably 0.10 to 1.0% by mass, even more preferably 0.20 to 0.80% by mass.

From the viewpoint of uniform application of the formulation, the mass ratio (A)/(E) of component (A) to component (E) in the aerosol concentrate is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.1 or more, and is preferably 60 or less, more preferably 10 or less, even more preferably 4 or less. The specific range of the mass ratio (A)/(E) of component (A) to component (E) in the aerosol concentrate is preferably 0.01 to 60, more preferably 0.03 to 10, even more preferably 0.1 to 4.

From the viewpoint of reducing skin irritation, the mass ratio (B)/(E) of component (B) to component (E) in the aerosol concentrate is preferably 0.01 or more, more preferably 0.05 or more, even more preferably 0.1 or more, and is preferably 100 or less, more preferably 14 or less, even more preferably 5 or less. The specific range of the mass ratio (B)/(E) of component (B) to component (E) in the aerosol concentrate is preferably 0.01 to 100, more preferably 0.05 to 14, even more preferably 0.1 to 5.

[Other optional ingredients]
The aerosol concentrate may contain other ingredients that are generally used in skin external preparations as appropriate, in addition to the above-mentioned ingredients. Examples of such ingredients include oils that are liquid at 25°C, polyhydric alcohols, thickeners, preservatives, powders, ethanol, antioxidants, colorants, fragrances, moisturizers, blood circulation promoters, cooling agents, antiperspirants, bactericides, whitening agents, anti-inflammatory agents, skin activators, etc. Note that each of these agents is not limited to its own use, and can be used for other purposes or can be used in combination with other purposes depending on the purpose. For example, the antiperspirant may be used as a fragrance, or it may be used to achieve the effects of both the antiperspirant and the fragrance.

The polyhydric alcohol may be any that is used in ordinary cosmetics, and examples thereof include dihydric polyhydric alcohols such as ethylene glycol, propylene glycol, propanediol, 1,3-butylene glycol, 1,3-propanediol, dipropylene glycol, polyethylene glycol, and polypropylene glycol; and trihydric or higher polyhydric alcohols such as glycerin and sorbitol. Among these, from the viewpoint of improving the penetration feeling and uniform application of the ejected agent into the skin, glycerin and dihydric polyols are preferred, glycerin, propylene glycol, propanediol, 1,3-butylene glycol, 1,3-propanediol, and dipropylene glycol are more preferred, glycerin, 1,3-propanediol, and dipropylene glycol are even more preferred, and it is even more preferred to include glycerin and dipropylene glycol.

From the viewpoint of improving the penetration feeling of the ejected agent into the skin and the uniform application property, the content of the polyhydric alcohol in the aerosol concentrate is preferably 1% by mass or more, more preferably 2% by mass or more, even more preferably 5% by mass or more, even more preferably 10% by mass or more, and is preferably 50% by mass or less, more preferably 40% by mass or less, even more preferably 30% by mass or less, even more preferably 20% by mass or less. The specific range of the content of the polyhydric alcohol in the aerosol concentrate is preferably 1 to 50% by mass, more preferably 2 to 40% by mass, even more preferably 5 to 30% by mass, even more preferably 10 to 20% by mass.

● Propellant [Component (D): Carbon dioxide gas]
In the present invention, the propellant contains carbon dioxide gas as component (D). As the propellant, in addition to carbon dioxide gas, other propellants can be used in combination. Examples of propellants other than carbon dioxide gas include liquefied petroleum gas (ethane, propane, ethylene, isobutane, normal butane, propylene, etc., mixed gases thereof (e.g., mixed gases of isobutane and propane, propane and butane, etc.)), ether-based propellants (dimethyl ether, etc.), fluorocarbons (fluorocarbons, chlorofluorocarbons, bromochlorofluorocarbons, etc.), compressed gases (nitrogen, air, mixed gases thereof, etc.), and fluorocarbon gases (monochlorodifluoroethane, tetrafluoroethane, etc.), among which nitrogen, dimethyl ether, and liquefied petroleum gas are preferred. When other propellants are used in combination with carbon dioxide gas as component (D), any of them can be used alone or in combination of two or more.

When a propellant other than carbon dioxide gas (component (D)) is used as a propellant, in order not to impair the effect of carbon dioxide gas, the ratio of carbon dioxide gas (component (D)) in the total propellant is preferably 20% or more, more preferably 40% or more, even more preferably 60% or more, and even more preferably 80% or more, based on the volume of the gaseous state (1013.25 hPa, 25°C).

Carbonate aerosol topical skin preparation The carbonate aerosol topical skin preparation of the present invention can be produced by preparing an aerosol concentrate containing components (A) to (C) and filling it into a pressure-resistant container together with a propellant containing component (D). The form of the spray is preferably a foam type that is discharged in the form of a foam.

The ratio of carbon dioxide gas to 100 parts by mass of the aerosol concentrate is preferably 0.01 parts by mass or more, more preferably 0.10 parts by mass or more, even more preferably 0.125 parts by mass or more, even more preferably 0.25 parts by mass or more, even more preferably 0.5 parts by mass or more, even more preferably 1.0 parts by mass or more, and is preferably 5.0 parts by mass or less, more preferably 3.0 parts by mass or less, from the viewpoint of improving the solubility of carbon dioxide gas in the aerosol concentrate, the foam viscosity, and the sprayability.

The pH of the mixture of the aerosol concentrate and the propellant containing carbon dioxide gas of component (D) is adjusted to 4.5 or more and 7.0 or less by the pH adjuster of component (B) from the viewpoint of improving the storage stability of the heparinoid. The pH of the mixture of the aerosol concentrate and the propellant is preferably 5.0 or more, more preferably 5.5 or more, and from the viewpoint of maintaining the pH of the skin after application at a weak acidity, it is preferably 6.5 or less, more preferably 6.0 or less. The pH of the mixture of the aerosol concentrate and the propellant can be determined by placing the aerosol concentrate with an indicator added in an aerosol compatibility bottle, filling it with propellant, and comparing the color tone with that of a standard. Bromophenol blue, bromocresol green, methyl red, bromothymol blue, etc. can be used as the indicator.

When the carbonic acid aerosol skin topical preparation of the present invention is a foam type, the viscosity of the discharged foam is preferably 0.1 Pa·s or more, more preferably 0.5 Pa·s or more, even more preferably 1.0 Pa·s or more, from the viewpoint of reducing irritation to the skin, and is preferably 50 Pa·s or less, more preferably 40 Pa·s or less, even more preferably 30 Pa·s or less. Here, the viscosity of the discharged foam is measured using a B-type viscometer (e.g., VISCOMETER TVB-10, manufactured by Toki Sangyo Co., Ltd.) under the conditions of rotor No. 3, 12 rpm, 25°C, and 10 seconds.

[How to use]
The carbonic acid aerosol skin topical agent of the present invention is applied in an appropriate amount to the skin, particularly to the skin of the whole body except the scalp, preferably to any of the face, body, limbs, etc., more preferably to the skin of the hands and feet, but may be taken by hand and spread on the target site, or may be directly ejected onto the target site. In the case of a foam type, it is preferable to take it in the hand and apply it without crushing the foam. In particular, it is preferable to apply it to the parts of the hands, feet, their fingers, heels, elbows, knees, etc., where the stratum corneum is thick and prone to drying. The amount of application is preferably about 1 g for both hands.

With regard to the above-described embodiment, further preferred aspects of the present invention are disclosed below.

<1> A carbonated aerosol skin preparation for topical use, which comprises an aerosol concentrate containing the following ingredients (A) to (C) and a propellant containing ingredient (D), and the pH of the mixture of the aerosol concentrate and the propellant is between 4.5 and 7.0.
(A) Heparinoids
(B) pH adjuster
(C) Water
(D) Carbon dioxide

<2> The carbonated aerosol skin topical preparation described in <1>, in which the content of component (A) in the aerosol concentrate is preferably 0.05% by mass or more, more preferably 0.07% by mass or more, even more preferably 0.1% by mass or more, and is preferably 0.6% by mass or less, more preferably 0.5% by mass or less, even more preferably 0.4% by mass or less.

<3> The carbonic acid aerosol skin preparation according to <1> or <2>, wherein component (B) is preferably one or more compounds selected from the group consisting of organic acids, organic acid salts, amino acids, amino acid salts, amines, inorganic acids, inorganic acid salts, and inorganic bases, more preferably one or more compounds selected from the group consisting of organic acids, organic acid salts, amino acids, amino acid salts, amines, and inorganic bases.

<4> A carbonated aerosol skin preparation according to any one of <1> to <3>, in which the content of component (B) in the aerosol concentrate is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.15% by mass or more, and is preferably 1.0% by mass or less, more preferably 0.7% by mass or less, even more preferably 0.5% by mass or less.

<5> A carbonated aerosol skin preparation according to any one of <1> to <4>, wherein the mass ratio (A)/(B) of component (A) to component (B) in the aerosol concentrate is preferably 0.05 or more, more preferably 0.1 or more, even more preferably 0.2 or more, and is preferably 12 or less, more preferably 5 or less, even more preferably 2.5 or less.

<6> A carbonated aerosol skin topical preparation according to any one of <1> to <5>, in which the content of component (C) in the aerosol concentrate is preferably 10% by mass or more, more preferably 20% by mass or more, even more preferably 40% by mass or more, and is preferably 90% by mass or less, more preferably 85% by mass or less, even more preferably 80% by mass or less.

<7> The carbonated aerosol skin preparation for topical use according to any one of <1> to <6>, preferably further comprising a water-soluble polymer as component (E) in the aerosol concentrate.

<8> The carbonated aerosol skin preparation according to <7>, wherein component (E) is preferably a water-soluble polymer having a sugar skeleton, more preferably a cellulose-based polymer, and even more preferably one or more selected from hydroxypropyl methylcellulose, hydroxypropyl methylcellulose stearoxy ether, and hydroxyethyl cellulose.

<9> The carbonated aerosol skin topical preparation according to <7> or <8>, in which the content of component (E) in the aerosol concentrate is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, even more preferably 0.10% by mass or more, even more preferably 0.20% by mass or more, and is preferably 5.0% by mass or less, more preferably 2.0% by mass or less, even more preferably 1.0% by mass or less, even more preferably 0.80% by mass or less.

<10> A carbonated aerosol skin preparation according to any one of <7> to <9>, wherein the mass ratio (A)/(E) of component (A) to component (E) in the aerosol concentrate is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.1 or more, and is preferably 60 or less, more preferably 10 or less, even more preferably 4 or less.

<11> The carbonic acid aerosol skin preparation according to any one of <7> to <10>, wherein the mass ratio (B)/(E) of component (B) to component (E) in the aerosol concentrate is preferably 0.01 or more, more preferably 0.05 or more, even more preferably 0.1 or more, and is preferably 100 or less, more preferably 14 or less, even more preferably 5 or less.

<12> The carbonated aerosol skin preparation for topical use according to any one of <1> to <11>, preferably further comprising a polyhydric alcohol in the aerosol concentrate.

<13> The carbonic acid aerosol skin topical preparation according to <12>, wherein the polyhydric alcohol is preferably one or more selected from glycerin and dihydric polyols, more preferably one or more selected from glycerin, propylene glycol, propanediol, 1,3-butylene glycol, 1,3-propanediol and dipropylene glycol, even more preferably one or more selected from glycerin, 1,3-propanediol and dipropylene glycol, even more preferably glycerin and dipropylene glycol.

<14> The carbonated aerosol skin topical preparation according to <12> or <13>, wherein the content of the polyhydric alcohol in the aerosol concentrate is preferably 1% by mass or more, more preferably 2% by mass or more, even more preferably 5% by mass or more, even more preferably 10% by mass or more, and is preferably 50% by mass or less, more preferably 40% by mass or less, even more preferably 30% by mass or less, even more preferably 20% by mass or less.

<15> The carbonic acid aerosol skin preparation according to any one of <1> to <14>, wherein the pH of the mixture of the aerosol concentrate and the propellant is preferably 5.0 or higher, more preferably 5.5 or higher, and is preferably 6.5 or lower, more preferably 6.0 or lower.

<16> The carbon dioxide aerosol skin preparation for external use according to any one of <1> to <15>, which is preferably discharged in the form of foam.

Examples 1 to 22, Comparative Examples 1 to 3
Aerosol concentrates were prepared according to the formulations shown in Tables 1 and 2, and filled into aluminum pressure containers together with propellants (carbon dioxide gas, isopentane, LPG) to produce carbonated aerosol skin cosmetics.
These carbonated aerosol skin cosmetics were evaluated for the stability of the heparinoid and the feel upon application according to the following methods and criteria.

The pH of the mixture of the aerosol concentrate and propellant was determined by placing the aerosol concentrate with added indicator in an aerosol compatibility bottle, filling it with propellant, and comparing the color with that of a standard. The indicators used were bromophenol blue (standard pH 4.0, 4.5, 4.7), bromocresol green (standard pH 5.0, 5.3, 5.5), methyl red (standard pH 5.0, 5.3, 5.5), etc.

<Stability of heparinoids>
The quantitative values of heparinoids after storing each aerosol skin preparation in a thermostatic chamber at 45°C for 3 months were compared with the initial quantitative values to calculate the residual rate of heparinoids, and the results were evaluated according to the following criteria. The quantitative determination of heparinoids was performed using ultraviolet-visible absorbance method with o-toluidine blue.
Residual rate of heparinoids (%) = (quantitative value after storage) / (initial quantitative value) x 100
A: Residual rate of heparinoids is 97% or more. B: Residual rate of heparinoids is 95% or more and less than 97%. C: Residual rate of heparinoids is 90% or more and less than 95%. D: Residual rate of heparinoids is 80% or more and less than 90%. E: Residual rate of heparinoids is less than 80%.

<Foam quality>
Approximately 1 g of the aerosol skin preparation was dispensed from a pressure-resistant container onto the palm of the hand, and the appearance of the foam after 10 seconds was evaluated by five expert panelists on the following scale: fine (2 points), coarse foam (1 point), or no foam (0 point). The total evaluation scores are shown in the table.

<Feel when applied>
0.5 g of the aerosol skin preparation was dispensed from a pressure-resistant container and applied to the forearm. Five expert panelists rated the skin sensation 5 minutes after spreading it out, on a scale of no tightness at all (2 points), almost no tightness (1 point), or tightness (0 point). The total scores are shown in the table.

*1: Metrose 90SH-15000 (manufactured by Shin-Etsu Chemical Co., Ltd.)

Claims (4)

It comprises an aerosol concentrate containing the following components (A) to (C) and (E) and a propellant containing component (D),
The mass ratio (A)/(B) of the component (A) to the component (B) is 0.2 to 30.00;
the mass ratio (A)/(E) of the component (A) to the component (E) is 0.1 to 4;
The pH of the mixture of the aerosol concentrate and the propellant is between 4.8 and 7.0.
The ratio of component (D) in the total propellant is 60% or more by volume in a gaseous state (1013.25 hPa, 25°C).
A carbonated aerosol skin treatment that is dispensed in foam form.
(A) Heparinoids: 0.05% by mass or more and 0.6% by mass or less
(B) pH adjuster 0.05 % by mass or more and 1.2% by mass or less
(C) Water
(D) Carbon dioxide
(E) Cellulosic polymer: 0.20% by mass or more and 0.80% by mass or less The carbonic acid aerosol skin preparation according to claim 1, wherein component (B) is one or more compounds selected from the group consisting of organic acids, organic acid salts, amino acids, amino acid salts, amines, and inorganic bases. The carbonated aerosol skin preparation according to claim 1 or 2, wherein component (E) is hydroxypropyl methylcellulose. The carbonic acid aerosol skin preparation according to any one of claims 1 to 3, wherein the mass ratio (B)/(E) of component (B) to component (E) is 0.01 or more and 5 or less.